

NICE TA Compliance

Calderdale Clinical Commissioning Group (CCG)

The technology appraisals listed on the following sheets as approved/funded by the CCG, are approved strictly in line with the conditions set out in the relevant NICE Technology Appraisal (TA). Use of drugs, devices and procedures outside of the scope of NICE TAs is strictly in line with CCG commissioning policies or by prior approval through individual funding requests only.

NICE (the National Institute for Health and Care Excellence) issues these guidelines after full consultation with experts within the NHS, in the expectation that the guidance is then followed by relevant NHS organisations such as hospitals and CCGs.

The TAs are presented in a table, with the most recent TA at the top of the page and then presented in descending order. By clicking on the title of the TA you will be linked automatically to the NICE website and the relevant guidance. The next two state whether or not the CCG supports the guidance with appropriate funding. If not, the final column explains why. For example, NHS England is responsible for funding cancer treatments rather than CCGs.

As new NICE TAs are published, this table will be updated.

Date Updated: September 2017

NICE TAs 2017-18

TA Number	TA Subject	Classification (Drug/Device/Procedure/Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA476	Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer	Drug	No	N/A	Responsibility of NHS England
TA475	Dimethyl fumarate for treating moderate to severe plaque psoriasis	Drug	Yes	Yes	
TA474	Sorafenib for treating advanced hepatocellular carcinoma	Drug	No	N/A	Responsibility of NHS England
TA473	Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck	Drug	No	N/A	Responsibility of NHS England
TA472	Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)	Drug	No	N/A	Responsibility of NHS England
TA471	Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)	Drug	Yes	Yes	

TA Number	TA Subject	Classification (Drug/Device/Procedure/Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA470	Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) (TA470)	Drug	No	N/A	N/A
TA469	Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) (TA469)	Drug	No	N/A	N/A
TA468	Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) (TA468)	Drug	No	N/A	N/A
TA467	Holoclar for treating limbal stem cell deficiency after eye burns (TA467)		No	N/A	Responsibility of NHS England
TA466	Baricitinib for moderate to severe rheumatoid arthritis (TA466)	Drug	Yes	Yes	
TA465	Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma (TA465)	Drug	No	N/A	Responsibility of NHS England
TA464	Bisphosphonates for treating osteoporosis (TA464)	Drug	Yes	Yes	

TA Number	TA Subject	Classification (Drug/Device/Procedure/Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA463	Cabozantinib for previously treated advanced renal cell carcinoma (TA463)	Drug	No	N/A	Responsibility of NHS England
TA462	Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)	Drug	No	N/A	Responsibility of NHS England
TA461	Roflumilast for treating chronic obstructive pulmonary disease (TA461)	Drug	Yes	Yes	
TA460	Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)	Drug	Yes	Yes	
TA459	Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)	Drug	Yes	Yes	
TA458	Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)	Drug	No	N/A	Responsibility of NHS England
TA457	Carfilzomib for previously treated multiple myeloma (TA457)	Drug	No	N/A	Responsibility of NHS England

TA Number	TA Subject	Classification (Drug/Device/Procedure/Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA456	Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)	Drug	Yes	Yes	
TA455	Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)	Drug	Yes	Yes	
TA454	Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA454)	Drug	No	N/A	
TA453	Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) (TA453)	Drug	No	N/A	
TA452	Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)	Drug	No	N/A	
TA451	Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia	Drug	No	N/A	Responsibility of NHS England

TA Number	TA Subject	Classification (Drug/Device/Procedure/Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA450	Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia	Drug	No	N/A	Responsibility of NHS England
TA449	Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease	Drug	No	N/A	Responsibility of NHS England
TA448	Etelcalcetide for treating secondary hyperparathyroidism	Drug	No	N/A	Responsibility of NHS England
TA447	Pembrolizumab for untreated PDL1-positive metastatic non-small-cell lung cancer	Drug	No	N/A	Responsibility of NHS England
TA446	Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma	Drug	No	N/A	Responsibility of NHS England
TA445	Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs	Drug	Yes	Yes	
TA444	Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)	Drug	No	N/A	

TA Number	TA Subject	Classification (Drug/Device/Procedure/Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA443	Obeticholic acid for treating primary biliary cholangitis	Drug	No	N/A	Responsibility of NHS England
TA442	Ixekizumab for treating moderate to severe plaque psoriasis	Drug	Yes	Yes	
TA441	Daclizumab for treating relapsing–remitting multiple sclerosis	Drug	No	N/A	Responsibility of NHS England
TA440	Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine	Drug	No	N/A	Responsibility of NHS England
TA439	Cetuximab and panitumumab for previously untreated metastatic colorectal cancer	Drug	No	N/A	Responsibility of NHS England
TA438	Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)	Drug	No	N/A	Responsibility of NHS England
TA437	Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)	Drug	No	N/A	
TA436	Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)	Drug	No	N/A	

TA Number	TA Subject	Classification (Drug/Device/Procedure/Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA435	Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal)	Drug	No	N/A	
TA434	Elotuzumab for previously treated multiple myeloma (terminated appraisal)	Drug	No	N/A	
TA433	Apremilast for treating active psoriatic arthritis	Drug	Yes	Yes	
TA432	Everolimus for advanced renal cell carcinoma after previous treatment	Drug	No	N/A	Responsibility of NHS England
TA431	Mepolizumab for treating severe refractory eosinophilic asthma	Drug	No	N/A	Responsibility of NHS England
TA430	Sofosbuvir–velpatasvir for treating chronic hepatitis C	Drug	No	N/A	Responsibility of NHS England
TA429	Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation	Drug	No	N/A	Responsibility of NHS England

TA Number	TA Subject	Classification (Drug/Device/Procedure/Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA428	Pembrolizumab for treating PDL1-positive non-small-cell lung cancer after chemotherapy	Drug	No	N/A	Responsibility of NHS England
TA427	Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib	Drug	No	N/A	Responsibility of NHS England

NICE TAs 2016-17

TA Number	TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA426	Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia	Drug	No	N/A	Responsibility of NHS England
TA425	Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia	Drug	No	N/A	Responsibility of NHS England
TA424	Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer	Drug	No	N/A	Responsibility of NHS England
TA423	Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens	Drug	No	N/A	Responsibility of NHS England
TA422	Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer	Drug	No	N/A	Responsibility of NHS England
TA421	Everolimus with exemestane for treating advanced breast cancer after endocrine therapy	Drug	No	N/A	Responsibility of NHS England

TA Number	TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA420	Ticagrelor for preventing atherothrombotic events after myocardial infarction	Drug	Yes	Yes	
TA419	Apremilast for treating moderate to severe plaque psoriasis	Drug	Yes	Yes	
TA418	Dapagliflozin in triple therapy for treating type 2 diabetes	Drug	Yes	Yes	
TA417	Nivolumab for previously treated advanced renal cell carcinoma	Drug	No	N/A	Responsibility of NHS England
TA416	Osimertinib for treating locally advanced or metastatic EGFR T790M mutationpositive non-small-cell lung cancer (TA416)(Oct 16)	Drug	no	N/A	responsibility of NHSE

TA Number	TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA415	Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)(Oct 16)	Drug	yes	yes	
TA414	Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)(Oct 16)	Drug	no	N/A	responsibility of NHSE
TA413	Elbasvir-grazoprevir for treating chronic hepatitis C (TA413)(Oct 16)	Drug	no	N/A	responsibility of NHSE

TA Number	TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA412	Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (replaces TA376) (TA412)(Sept 16)	Drug	no	N/A	responsibility of NHSE
TA411	Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)(Sept 16)	Drug	no	N/A	responsibility of NHSE
TA410	Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)(Sept 16)	Drug	no	N/A	responsibility of NHSE

TA Number	TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA409	Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)(Sept 16)	Drug	yes	Yes	
TA408	Pegaspargase for treating acute lymphoblastic leukaemia (TA408)(Sept 16)	Drug	no	N/A	responsibility of NHSE
TA407	Secukinumab for active ankylosing spondylitis after treatment with nonsteroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407) (Sept 16)	Drug	yes	Yes	

TA Number	TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA406	Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)(Sept 16)	Drug	no	N/A	responsibility of NHSE
TA405	Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)(Aug 16)	Drug	no	na	responsibility of NHSE
TA404	Degarelix for treating advanced hormone-dependent prostate cancer (TA404) (Aug 16)	Drug	yes	yes	

TA Number	TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA403	Ramucirumab for previously treated locally advanced or metastatic non-smallcell lung cancer (TA403) (Aug 16)	Drug	no	na	responsibility of NHSE (not recommended)
TA402	Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402) (Aug 16)	Drug	no	na	responsibility of NHSE
TA401	Bosutinib for previously treated chronic myeloid leukaemia (TA401) (Aug 16)	Drug	no	na	responsibility of NHSE

TA Number	TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA400	Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400) (Jul 16)	Drug	no	na	responsibility of NHSE
TA399	Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399) (Jul 16)	Drug	no	na	responsibility of NHSE (not recommended)
TA398	Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398) (Jul 16)	Drug	no	na	responsibility of NHSE (not recommended)

TA Number	TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA397	Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397) (Jun 16)	Drug	no	NA	responsibility of NHSE
TA396	Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)(Jun 16)	Drug	no	NA	responsibility of NHSE
TA395	Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)(Jun 16)	Drug	no	NA	responsibility of NHSE

TA Number	TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA394	Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)(Jun 16)	Drug	yes	yes	
TA393	Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393) (june 16)	Drug	yes	yes	
TA392	Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392) (May 16)	Drug	no	NA	Responsibility of NHSE

TA Number	TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA391	Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391) (May 16 updated Aug 16)	Drug	no	NA	responsibility of NHSE
TA390	Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)(May 16)	Drug	yes	yes	
TA389	Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)(Apr 16)	Drug	no	NA	responsibility of NHSE (Replaces TA91 and TA222)

TA Number	TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
TA388	Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)(Apr 16)	Drug	yes	yes	
TA387	Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)(Apr 16 updated July 16)	Drug	no	NA	Responsibility of NHSE

NICE TAs 2015-16

TA Subject	Classification (Drug/Device/Pr ocedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)(Mar 16)	Drug	no	NA	Responsibility of NHSE
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)(Feb 16)	Drug	yes	yes	
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)(Feb 16)	Drug	no	No	Responsible for NHSE
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)(Feb 16)	Drug	yes	yes	

TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)(TA 382)(Jan 16)	Drug	yes	No	Terminated appraisal
Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)(Jan 16)	Drug	no	No	Responsibility of NHSE
Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380) (Jan 16)	Drug	No	No	Responsibility of NHSE

TA Subject	Classification (Drug/Device/Pr ocedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380) (Jan 16)	Drug	no	No	Responsibility of NHSE
Nintedanib for treating idiopathic pulmonary fibrosis (TA379) (Jan 16)	Drug	yes	No	Responsibility of NHSE
Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378) (Jan 16)	Drug	no	NA	Responsibility of NHSE (not recommended)
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)(Jan 16)	Drug	no	N/A	Responsibility of NHSE
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastase (TA376)(Jan 16)	Drug	no	N/A	Responsibility of NHSE

TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375) (Jan 15)	Drug	yes	Yes	
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374) (Dec 15)	Drug	no	n/a	Responsibility of NHSE
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373) (Dec 15)	Drug	no	NA	Responsibility of NHSE
Apremilast for treating active psoriatic arthritis (TA372) (Dec 15)	Drug	Yes	No	Not recommended

TA Subject	Classification (Drug/Device/Pr ocedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane (TA371) (Dec 15)	Drug	No	N/A	Responsibility of NHSE (not recommended)
Bortezomib for previously untreated mantle cell lymphoma (Dec 15)	Drug	No	N/A	Responsibility of NHSE
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369) (Dec 15)	Drug	Yes	Yes	
Apremilast for treating moderate to severe plaque psoriasis (TA368) (Nov 15)	Drug	yes	No	Not recommended
Vortioxetine for treating major depressive episodes (TA367) (Nov 15)	Drug	Yes	Yes	

TA Subject	Classification (Drug/Device/Pr ocedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366) (Nov 15)	Drug	No	N/A	Responsibility of NHSE
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)(Nov 15)	Drug	No	N/A	Responsibility of NHSE
Daclatasvir for treating chronic hepatitis C (TA364)	Drug	No	N/A	Responsibility of NHSE
Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)	Drug	No	N/A	Responsibility of NHSE
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA 362)	Drug	No	N/A	Responsibility of NHSE (terminated appraisal)

TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) (TA361)	Drug	No	NA	Responsibility of NHSE (terminated appraisal)
Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (TA360)	Drug	No	N/A	Responsibility of NHSE
Idelalisib for treating chronic lymphocytic leukaemia (TA359)	Drug	No	N/A	Responsibility of NHSE
Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)	Drug	Yes	Yes	
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)	Drug	No	N/A	Responsibility of NHSE

TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Ruxolitinib for treating polycythaemia vera (terminated appraisal)(TA356)(Sept15)	Drug	N/A	N/A	TERMINATED APPRAISAL - NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating polycythaemia vera that is resistant to hydroxycarbamide or for people who cannot tolerate hydroxycarbamide because no evidence submission was received from Novartis Pharmaceuticals for the technology.
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)(Sept15)	Drug	Yes	Yes	
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)(Aug15)	Drug	Yes	Yes	

TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)(TA353)(Aug15)	Drug	N/A	N/A	TERMINATED APPRAISAL - NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer because no evidence submission was received from Roche Products for the technology.
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)(Aug15)	Drug	Yes	Yes	

TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Cangrelor for reducing atherothrombotic events in people undergoing PCI or awaiting surgery requiring interruption of anti-platelet therapy (TA351)(July15)	Drug	N/A	N/A	<p>TERMINATED APPRAISAL - NICE is unable to make a recommendation about the use in the NHS of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy because no evidence submission was received from The Medicines Company.</p>
Secukinumab for treating moderate to severe plaque psoriasis (TA350)(July15)	Drug	Yes	Yes	
Dexamethasone intravitreal implant for diabetic macular oedema (TA349)(July15)	Drug	Yes	Yes	
Everolimus for preventing organ rejection in liver transplant (TA348)(July15)	Drug	No	N/A	<p>Responsibility of NHSE (Everolimus is not recommended within its marketing authorisation for preventing organ rejection in people having a liver transplant)</p>

TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small cell lung cancer (TA347)(July15)	Drug	No	N/A	Responsibility of NHSE
Aflibercept for treating diabetic macular oedema (TA346)(July15)	Drug	Yes	Yes	
Naloxegol for treating opioid induced constipation (TA345)(July15)	Drug	Yes	Yes	
Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (TA344) (Jun15)	Drug	No	N/A	Responsibility of NHSE
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343) (Jun15)	Drug	No	N/A	Responsibility of NHSE
Vedolizumab for treating moderately to severely active ulcerative colitis (TA342) (Jun15)	Drug	Yes	Yes	
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341) (Jun15)	Drug	Yes	Yes	

TA Subject	Classification (Drug/Device/Pr ocedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Ustekinumab for treating active psoriatic arthritis (TA340) (Jun15)	Drug	Yes	Yes	
Omalizumab for previously treated chronic spontaneous urticaria (TA339) (Jun15)	Drug	No	N/A	Responsibility of NHSE

NICE TAs 2014-15

TA Subject	Classification (Drug/Device/ Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (TA338) (Mar15)	Drug	No	N/A	Responsibility of NHSE (Not routinely funded in line with NICE recommendations)
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337) (Mar15)	Drug	Yes	Yes	
Empagliflozin in combination therapy for treating type 2 diabetes (TA336) (Mar15)	Drug	Yes	Yes	
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335) (Mar15)	Drug	Yes	Yes	
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334) (Feb15)	Drug	No	N/A	Responsibility of NHSE (Not routinely funded: terminated appraisal)
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333) (Feb15)	Drug	No	N/A	Responsibility of NHSE
Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer (TA332) (Feb15)	Drug	No	N/A	Responsibility of NHSE (Not routinely funded in line with NICE recommendations)

TA Subject	Classification (Drug/Device/ Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (TA 331) (Feb15)	Drug	No	N/A	Responsibility of NHSE
Sofosbuvir for treating chronic hepatitis C (TA330) (Feb15)	Drug	No	N/A	Responsibility of NHSE
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329) (Feb15)	Drug	Yes	Yes	Includes a review of TA140 and TA262
Eculizumab for treating atypical haemolytic uraemic syndrome (HST1) (Jan15)	Drug	No	N/A	Responsibility of NHSE (specialised commissioning)
Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) (TA328) (Dec14)	Drug	No	N/A	Responsibility of NHSE (Not routinely funded: terminated appraisal)
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327) (Dec14)	Drug	Yes	Yes	
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326) (Nov14)	Drug	No	N/A	Responsibility of NHSE (Review of NICE TA196)
Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325) (Nov14)	Drug	Yes	Yes	

TA Subject	Classification (Drug/Device/ Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (TA324) (Nov14)	Device	Yes	Yes	Part review of TA8
Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323) (Nov14)	Drug	Yes	Yes	Includes review of TA142
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321) (Oct14)	Drug	No	N/A	Responsibility of NHS England
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322) (Sep14)	Drug	No	N/A	Responsibility of NHS England
Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320) (Aug14)	Drug	No	N/A	Responsibility of NHS England
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319) (Jul14)	Drug	No	N/A	Responsibility of NHS England
Lubiprostone for treating chronic idiopathic constipation (TA318) (Jul14)	Drug	Yes	Yes	
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317) (Jul14)	Drug	Yes	Yes	Review of NICE TA182

TA Subject	Classification (Drug/Device/ Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen (TA316) (Jul14)	Drug	No	N/A	Responsibility of NHS England
Canagliflozin in combination therapy for treating type 2 diabetes (TA315) (Jun14)	Drug	Yes	Yes	
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (review of TA95 and TA120) (TA314) (Jun14)	Device	Yes	Yes	
Psoriatic arthritis (active) - ustekinumab (TA313) (May 14)	Drug	Yes	N/A	Not routinely funded, in line with NICE recommendation. Ustekinumab is not recommended for active psoriatic arthritis when treatment with non-biological disease-modifying antirheumatic drugs (or DMARDs) has not worked well enough.
Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312) (May14)	Drug	No	N/A	Responsibility of NHS England
Multiple myeloma - bortezomib (induction therapy) (TA311) (Apr14)	Drug	No	N/A	Responsibility of NHS England
Lung cancer (non small cell, EGFR mutation positive) - afatinib (TA310) (Apr14)	Drug	No	N/A	Responsibility of NHS England

TA Subject	Classification (Drug/Device/ Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Lung cancer (non small cell, non squamous) - pemetrexed (TA309) (Apr14)	Drug	No	N/A	Responsibility of NHS England. Pemetrexed is not recommended as maintenance treatment for people with locally advanced or metastatic non-squamous non-small-cell lung cancer after therapy with pemetrexed and cisplatin.

NICE TAs 2013-14

TA Subject	Classification (Drug/Device /Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)	Drug	No	N/A	Responsibility of NHS England
Colorectal cancer (metastatic) - aflibercept (TA307)	Drug	No	N/A	Responsibility of NHS England
Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (TA306) (Feb'14)	Drug	No	N/A	Responsibility of NHS England
Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (TA305) (Feb'14)	Drug	Yes	Yes	
Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (Rev TA2, TA44) (TA304) (Feb'14)	Procedure	Yes	Yes	
Multiple sclerosis (relapsing) - teriflunomide (TA303) (Jan'14)	Drug	No	N/A	Responsibility of NHS England
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302) (Nov'13)	Drug	Yes	N/A	Terminated Appraisal. Not routinely funded in line with NICE recommendation.
Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) (TA301) (Nov'13)	Drug	Yes	Yes	
Hepatitis C (children and young people) - peginterferon alfa and ribavirin (TA300) (Nov'13)	Drug	No	N/A	Responsibility of NHS England
Bosutinib for previously treated chronic myeloid leukaemia (TA299) (Nov'13)	Drug	No	N/A	Responsibility of NHS England. NICE does not recommend bosutinib for previously treated chronic myeloid leukaemia
Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298) (Nov'13)	Drug	Yes	Yes	

TA Subject	Classification (Drug/Device/ Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Vitreomacular traction - ocriplasmin (TA297) (October '13)	Drug	Yes	Yes	
Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib (TA296) (September '13)	Drug	No	N/A	Responsibility of NHS England. NICE does not recommend crizotinib for people with a type of advanced non-small-cell lung cancer that is 'ALK-positive' and has been treated before.
Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) (TA295) (August '13)	Drug	No	N/A	Responsibility of NHS England. Not routinely funded in line with NICE recommendation. NICE does not recommend the use of everolimus, in combination with exemestane, for treating postmenopausal women with advanced HER2 negative hormone receptor-positive breast cancer that has recurred or progressed following treatment with a non-steroidal aromatase
Macular degeneration (wet age-related) aflibercept (TA294) (July '13)	Drug	Yes	Yes	
Thrombocytopenic purpura - eltrombopag (TA293) (July '13)	Drug	Yes	Yes	
Bipolar disorder (children) - aripiprazole (TA292) (July '13)	Drug	Yes	Yes	
Gout (tophaceous, severe debilitating, chronic) - pegloticase (TA291) (June '13)	Drug	No	N/A	Not routinely funded in line with NICE recommendation. NICE does not recommend pegloticase for people who have severe, chronic gout with tophi who have either tried oral gout drugs and still have high uric acid levels, or cannot take oral gout drugs.

TA Subject	Classification (Drug/Device/ Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Overactive bladder - mirabegron (TA290) (June '13)	Drug	Yes	Yes	
Myelofibrosis (splenomegaly, symptoms) - ruxolitinib (TA289) (June'13)	Drug	No	N/A	Not routinely funded in line with NICE recommendation. NICE does not recommend ruxolitinib for people with an enlarged spleen or symptoms from myelofibrosis.
Type 2 diabetes - Dapagliflozin combination therapy (TA288) (June '13)	Drug	Yes	Yes	
Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (TA287) (June '13)	Drug	Yes	Yes	
Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286) (May'13)	Drug	No	N/A	Terminated Appraisal. Not routinely funded in line with NICE recommendation.
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285) (May'13)	Drug	No	N/A	Responsibility of NHS England. Bevacizumab in combination with gemcitabine and carboplatin is not recommended for treating people with first recurrence of platinum-sensitive advanced ovarian cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.

TA Subject	Classification (Drug/Device /Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284) (May'13)	Drug	No	N/A	Responsibility of NHS England. NICE does not recommend bevacizumab, given with paclitaxel and carboplatin, as first-line treatment for advanced ovarian cancer (including fallopian tube and primary peritoneal cancer).
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283) (May'13)	Drug	Yes	Yes	
Pirfenidone for treating idiopathic pulmonary fibrosis (TA282) (Apr'13)	Drug	No	N/A	Responsibility of NHS England
Gout - canakinumab (terminated appraisal) (TA281) (Apr'13)	Drug	No	N/A	Terminated Appraisal. Not routinely funded in line with NICE recommendation.
Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (rapid review of technology appraisal guidance 234) (TA280) (Apr'13)	Drug	Yes	Yes	Replaces NICE TA234
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures (TA279) (Apr'13)	Procedure	Yes	Yes	Procedure (level 2 or below) commissioned by CCG. Specialist spinal surgery commissioned by NHS E
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults (review of TA133 and TA201) (TA278) (Apr'13)	Drug	No	N/A	Responsibility of NHS England

NICE TAs 2012-13

TA Subject	Classification (Drug/Device/Pr ocedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) (TA277)	Drug	<u>No</u>	<u>N/A</u>	Terminated Appraisal. Not routinely funded in line with NICE recommendation.
Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)	Drug	<u>No</u>	<u>N/A</u>	Responsibility of NHS England
Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)	Drug	<u>Yes</u>	<u>Yes</u>	
Macular oedema (diabetic) - ranibizumab (TA274)	Drug	<u>Yes</u>	<u>Yes</u>	
Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273)	Drug	<u>No</u>	<u>N/A</u>	Terminated Appraisal. Not routinely funded in line with NICE recommendation.
Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)	Drug	<u>No</u>	<u>N/A</u>	Responsibility of NHS England
Diabetic macular oedema - fluocinolone acetonide intravitreal implant (TA271)	Drug	<u>Yes</u>	<u>N/A</u>	Not routinely funded in line with NICE recommendation.
Leukaemia (acute myeloid) - decitabine (terminated appraisal) (TA270)	Drug	<u>No</u>	<u>N/A</u>	Responsibility of NHS England
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)	Drug	<u>No</u>	<u>N/A</u>	Responsibility of NHS England
Melanoma (stage III or IV) - ipilimumab (TA268)	Drug	<u>No</u>	<u>N/A</u>	Responsibility of NHS England

TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Chronic heart failure - ivabradine (TA267)	Drug	Yes	Yes	
Cystic fibrosis - mannitol dry powder for inhalation (TA266)	Drug	No	N/A	Responsibility of NHS England
Bone metastases from solid tumours - denosumab (TA265)	Drug	No	N/A	Responsibility of NHS England
Stroke (acute, ischaemic) - alteplase (TA264)	Drug	Yes	Yes	Included in PbR tariff
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)	Drug	No	N/A	Responsibility of NHS England
Ulcerative colitis (moderate to severe, second line) - adalimumab (terminated appraisal) (TA262)	Drug	Yes	No	Terminated Appraisal. Not routinely funded in line with NICE recommendation
Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban (TA261)	Drug	Yes	Yes	
Migraine (chronic) - botulinum toxin type A (TA260)	Drug	Yes	Yes	
Prostate cancer (metastatic, castration resistant) - abiraterone (following cytotoxic therapy) (TA259)	Drug	No	N/A	Responsibility of NHS England
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) (TA258)	Drug	No	N/A	Responsibility of NHS England
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) (TA257)	Drug	No	N/A	Responsibility of NHS England

TA Subject	Classification (Drug/Device/Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)	Drug	<u>Yes</u>	<u>Yes</u>	
Prostate cancer - cabazitaxel (TA255)	Drug	<u>No</u>	<u>N/A</u>	Responsibility of NHS England
Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)	Drug	<u>No</u>	<u>N/A</u>	Responsibility of NHS England
Hepatitis C (genotype 1) - boceprevir (TA253)	Drug	<u>No</u>	<u>N/A</u>	Responsibility of NHS England
Hepatitis C (genotype 1) - telaprevir (TA252)	Drug	<u>No</u>	<u>N/A</u>	Responsibility of NHS England
Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib (TA251)	Drug	<u>No</u>	<u>N/A</u>	Responsibility of NHS England
Breast cancer (advanced) - eribulin (TA250)	Drug	<u>No</u>	<u>N/A</u>	Responsibility of NHS England

NICE TAs 2011-12

TA Subject	Classification (Drug/Device /Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Atrial fibrillation - dabigatran etexilate (TA249)	Drug	Yes	Yes	
Diabetes (type 2) - exenatide (prolonged release) (TA248)	Drug	Yes	Yes	
Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247)	Drug	Yes	Yes	
Venom anaphylaxis - immunotherapy pharmlagen (TA246)	Drug	No	N/A	Responsibility of NHS England
Venous thromboembolism - apixaban (hip and knee surgery) (TA245)	Drug	Yes	Yes	Included in PbR tariff for procedures
Chronic obstructive pulmonary disease - roflumilast (TA244)	Drug	Yes	Yes	
Follicular lymphoma - rituximab (review) (TA243)	Drug	No	N/A	Responsibility of NHS England
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) (TA242)	Drug	No	N/A	Responsibility of NHS England
Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) (TA241)	Drug	No	N/A	Responsibility of NHS England
Colorectal cancer (metastatic) - panitumumab (terminated appraisal) (TA240)	Drug	No	N/A	Responsibility of NHS England
Breast cancer (metastatic) - fulvestrant (TA239)	Drug	No	N/A	Responsibility of NHS England

TA Subject	Classification (Drug/Device /Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)	Drug	Yes	Yes	
Macular oedema (diabetic) - ranibizumab (TA237)	Drug	Yes	N/A	Replaced by TA274
Acute coronary syndromes - ticagrelor (TA236)	Drug	Yes	Yes	
Osteosarcoma - mifamurtide (TA235)	Drug	No	N/A	Responsibility of NHS England
Rheumatoid arthritis - abatacept (2nd line) (TA234)	Drug	Yes	No	Not routinely funded in line with NICE recommendation (superceded by TA280)
Ankylosing spondylitis - golimumab (TA233)	Drug	Yes	Yes	
Epilepsy (partial) - retigabine (adjuvant) (TA232)	Drug	Yes	Yes	
Depression - agomelatine (terminated appraisal) (TA231)	Drug	Yes	No	Not routinely funded in line with NICE recommendation
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)	Drug	Yes	Yes	
Macular oedema (retinal vein occlusion) - dexamethasone (TA229)	Drug	Yes	Yes	
Multiple myeloma (first line) - bortezomib and thalidomide (TA228)	Drug	No	N/A	Responsibility of NHS England
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) (TA227)	Drug	No	N/A	Responsibility of NHS England

TA Subject	Classification (Drug/Device /Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)	Drug	No	N/A	Responsibility of NHS England
Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab (TA225)	Drug	Yes	Yes	
Rheumatoid arthritis (methotrexate-naïve) - golimumab (terminated appraisal) (TA224)	Drug	Yes	No	Terminated Appraisal. Not routinely funded in line with NICE recommendation.
Peripheral arterial disease - cilostazol, naftidofyryl oxalate, pentoxifylline and inositol nicotinate (TA223)	Drug	Yes	Yes	
Ovarian cancer (relapsed) - trabectedin (TA222)	Drug	No	N/A	
Thrombocytopenic purpura - romiplostim (TA221)	Drug	Yes	Yes	
Psoriatic arthritis - golimumab (TA220)	Drug	Yes	Yes	
Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)	Drug	No	N/A	Responsibility of NHS England

NICE TAs 2010-11

TA Subject	Classification (Drug/Device /Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Myelodysplastic syndromes - azacitidine (TA218)	Drug	No	N/A	Responsibility of NHS England
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (TA217)	Drug	Yes	Yes	
Leukaemia (lymphocytic) - bendamustine (TA216)	Drug	No	N/A	Responsibility of NHS England
Renal cell carcinoma (first line metastatic) - pazopanib (TA215)	Drug	No	N/A	Responsibility of NHS England
Breast cancer - bevacizumab (in combination with a taxane) (TA214)	Drug	No	N/A	Responsibility of NHS England
Schizophrenia - aripiprazole (TA213)	Drug	Yes	Yes	
Colorectal cancer (metastatic) - bevacizumab (TA212)	Drug	No	N/A	Responsibility of NHS England
Constipation (women) - prucalopride (TA211)	Drug	Yes	Yes	
Vascular disease - clopidogrel and dipyridamole (TA210)	Drug	Yes	Yes	
Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209)	Drug	No	N/A	Responsibility of NHS England
Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208)	Drug	No	N/A	Responsibility of NHS England
Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal) (TA207)	Drug	No	N/A	Responsibility of NHS England

TA Subject	Classification (Drug/Device /Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Lymphoma (non-Hodgkin's) - bendamustine (terminated appraisal) (TA206)	Drug	No	N/A	Responsibility of NHS England
Thrombocytopenic purpura - eltrombopag (TA205)	Drug	Yes	Yes	
Osteoporotic fractures - denosumab (TA204)	Drug	Yes	Yes	
Diabetes (type 2) - liraglutide (TA203)	Drug	Yes	Yes	
Chronic lymphocytic leukaemia - ofatumumab (TA202)	Drug	No	N/A	Responsibility of NHS England
Asthma (in children) - omalizumab (TA201)	Drug	No	N/A	Responsibility of NHS England
Hepatitis C - peginterferon alfa and ribavirin (TA200)	Drug	No	N/A	Responsibility of NHS England
Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)	Drug	Yes	Yes	
Atrial fibrillation - dronedarone (TA197)	Drug	Yes	Yes	
Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196)	Drug	No	N/A	Responsibility of NHS England
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)	Drug	Yes	Yes	
Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal) (TA194)	Drug	No	N/A	Responsibility of NHS England
Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193)	Drug	No	N/A	Responsibility of NHS England
Lung cancer (non-small-cell, first line) - gefitinib (TA192)	Drug	No	N/A	Responsibility of NHS England

TA Subject	Classification (Drug/Device /Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Gastric cancer (advanced) - capecitabine (TA191)	Drug	No	N/A	Responsibility of NHS England
Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)	Drug	No	N/A	Responsibility of NHS England
Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) (TA189)	Drug	No	N/A	Responsibility of NHS England
Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188)	Drug	Yes	Yes	
Crohn's disease - infliximab (review) and adalimumab (review of TA40) (TA187)	Drug	Yes	Yes	

NICE TAs 2009-10

TA Subject	Classification (Drug/Device/Procedure/Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Rheumatoid arthritis - certolizumab pegol (TA186)	Drug	Yes	Yes	
Soft tissue sarcoma - trabectedin (TA185)	Drug	No	N/A	Responsibility of NHS England
Lung cancer (small-cell) - topotecan (TA184)	Drug	No	N/A	Responsibility of NHS England
Cervical cancer (recurrent) - topotecan (TA183)	Drug	No	N/A	Responsibility of NHS England
Acute coronary syndrome - prasugrel (TA182)	Drug	Yes	Yes	
Lung cancer (non-small-cell, first line treatment) - pemetrexed (TA181)	Drug	No	N/A	
Psoriasis - ustekinumab (TA180)	Drug	Yes	Yes	
Gastrointestinal stromal tumours - sunitinib (TA179)	Drug	No	N/A	Responsibility of NHS England
Renal cell carcinoma (TA178)	Drug	No	N/A	Responsibility of NHS England
Eczema (chronic) - alitretinoin (TA177)	Drug	Yes	Yes	
Colorectal cancer (first line) - cetuximab (TA176)	Drug	No	N/A	Responsibility of NHS England
Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal) (TA175)	Drug	No	N/A	Responsibility of NHS England
Leukaemia (chronic lymphocytic, first line) - rituximab (TA174)	Drug	No	N/A	Responsibility of NHS England
Hepatitis B - tenofovir disoproxil fumarate (TA173)	Drug	No	N/A	Responsibility of NHS England
Head and neck cancer (squamous cell carcinoma) - cetuximab (TA172)	Drug	No	N/A	Responsibility of NHS England
Multiple myeloma - lenalidomide (TA171)	Drug	No	N/A	Responsibility of NHS England
Venous thromboembolism - rivaroxaban (TA170)	Drug	Yes	Yes	Included in PbR tariff for procedures

NICE TAs pre April 2009

TA Subject	Classification (Drug/Device/ Procedure/ Other)	Applicable to CCGs (Yes/No)	Funding agreed for treatment in line with Technology Appraisal	Comments
Renal cell carcinoma - sunitinib (TA169)	Drug	No	N/A	
Influenza - zanamivir, amantadine and oseltamivir (review) (TA168)	Drug	Yes	Yes	
Abdominal aortic aneurysm - endovascular stent-grafts (TA167)	Procedure	Yes	Yes	
Hearing impairment - cochlear implants (TA166)	Device	No	N/A	Responsibility of NHS England
Organ preservation (renal) - machine perfusion and static storage (TA165)	Procedure	No	N/A	Responsibility of NHS England
Hyperuricaemia - febuxostat (TA164)	Drug	Yes	Yes	
Ulcerative colitis (acute exacerbations) - infliximab (TA163)	Drug	Yes	Yes	
Lung cancer (non-small-cell) - erlotinib (TA162)	Drug	No	N/A	Responsibility of NHS England
Osteoporosis - secondary prevention including strontium ranelate (TA161)	Drug	Yes	Yes	
Osteoporosis - primary prevention (TA160)	Drug	Yes	Yes	
Pain (chronic neuropathic or ischaemic) - spinal cord stimulation (TA159)	Procedure	Yes	Yes	
Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir (TA158)	Drug	Yes	N/A	Updated by TA168. Funded in line with TA 168
Venous thromboembolism - dabigatran (TA157)	Drug	Yes	Yes	Included in PbR tariff for procedures
Pregnancy (rhesus negative women) - routine anti-D (review) (TA156)	Drug	Yes	Yes	
Macular degeneration (age-related) - ranibizumab and pegaptanib (TA155)	Drug	Yes	Yes	
Hepatitis B - telbivudine (TA154)	Drug	No	N/A	Responsibility of NHS England
Hepatitis B - entecavir (TA153)	Drug	No	N/A	Responsibility of NHS England
Coronary artery disease - drug-eluting stents (TA152)	Device	Yes	Yes	
Diabetes - insulin pump therapy (TA151)	Device	Yes	Yes	

Glioma (recurrent) - carmustine implants (terminated appraisal) (TA149)	Drug	No	N/A	Responsibility of NHS England
Lung cancer (non-small-cell) - bevacizumab (terminated appraisal) (TA148)	Drug	No	N/A	Responsibility of NHS England
Psoriasis - adalimumab (TA146)	Drug	Yes	Yes	
Head and neck cancer - cetuximab (TA145)	Drug	No	N/A	Responsibility of NHS England
Ankylosing spondylitis - adalimumab, etanercept and infliximab (TA143)	Drug	Yes	Yes	
Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin (TA142)	Drug	No	N/A	Responsibility of NHS England
Ulcerative colitis (subacute manifestations) - infliximab (TA140)	Drug	Yes	No	Not routinely funded in line with NICE TA
Sleep apnoea - continuous positive airway pressure (CPAP) (TA139)	Device	Yes	Yes	
Asthma (in adults) - corticosteroids (TA138)	Drug	Yes	Yes	
Lymphoma (follicular non-Hodgkin's) - rituximab (TA137)	Drug	No	N/A	Responsibility of NHS England
Structural neuroimaging in first-episode psychosis (TA136)	Procedure	Yes	N/A	Not routinely funded in line with NICE recommendation.
Mesothelioma - pemetrexed disodium (TA135)	Drug	No	N/A	Responsibility of NHS England
Psoriasis - infliximab (TA134)	Drug	Yes	Yes	
Asthma (uncontrolled) - omalizumab (TA133)	Drug	Yes	Yes	
Hypercholesterolaemia - ezetimibe (TA132)	Drug	Yes	Yes	
Asthma (in children) - corticosteroids (TA131)	Drug	Yes	Yes	
Rheumatoid arthritis - adalimumab, etanercept and infliximab (TA130)	Drug	Yes	N/A	Responsibility of NHS England
Multiple myeloma - bortezomib (TA129)	Drug	No	N/A	Responsibility of NHS England
Haemorrhoid - stapled haemorrhoidopexy (TA128)	Procedure	Yes	Yes	
Multiple sclerosis - natalizumab (TA127)	Drug	No	N/A	Responsibility of NHS England
Lung cancer (non-small-cell) - pemetrexed (TA124)	Drug	No	N/A	Responsibility of NHS England
Smoking cessation - varenicline (TA123)	Drug	No	N/A	Commissioned by Public Health/Local Authority
Ischaemic stroke (acute) - alteplase (TA122)	Drug	Yes	Yes	
Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide (TA121)	Drug	No	N/A	Responsibility of NHS England

Heart failure - cardiac resynchronisation (TA120)	Procedure	No	N/A	Responsibility of NHS England
Leukaemia (lymphocytic) - fludarabine (TA119)	Drug	No	N/A	Responsibility of NHS England
Colorectal cancer (metastatic) - bevacizumab and cetuximab (TA118) (partially updated by TA242)	Drug	No	N/A	Responsibility of NHS England
Hyperparathyroidism - cinacalcet (TA117)	Drug	Yes	Yes	
Breast cancer - gemcitabine (TA116)	Drug	No	N/A	Responsibility of NHS England
Drug misuse - naltrexone (TA115)	Drug	No	N/A	Commissioned by Public Health/Local Authority
Drug misuse - methadone and buprenorphine (TA114)	Drug	No	N/A	Commissioned by Public Health/Local Authority
Breast cancer (early) - hormonal treatments (TA112)	Drug	No	N/A	Responsibility of NHS England
Breast cancer (early) - docetaxel (TA109)	Drug	No	N/A	Updated by CG80 Responsibility of NHS England
Breast cancer (early) - paclitaxel (TA108)	Drug	No	N/A	Updated by CG80 Responsibility of NHS England
Breast cancer (early) - trastuzumab (TA107)	Drug	No	N/A	Updated by CG80 Responsibility of NHS England
Hepatitis C - peginterferon alfa and ribavirin (TA106)	Drug	No	N/A	Responsibility of NHS England
Colorectal cancer - laparoscopic surgery (review) (TA105)	Procedure	Yes	Yes	
Psoriasis - efalizumab and etanercept (TA103)	Drug	Yes	Yes	
Conduct disorder in children - parent-training/education programmes (TA102)	Other	Yes	Yes	
Prostate cancer (hormone-refractory) - docetaxel (TA101)	Drug	No	N/A	Responsibility of NHS England
Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)	Drug	No	N/A	Responsibility of NHS England
Renal transplantation - immunosuppressive regimens for children and adolescents (TA99)	Drug	No	N/A	Responsibility of NHS England
Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review) (TA98)	Drug	Yes	Yes	
Depression and anxiety - computerised cognitive behavioural therapy (CCBT) (TA97)	Other	Yes	Yes	

Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a (TA96)	Drug	No	N/A	Responsibility of NHS England
Arrhythmia - implantable cardioverter defibrillators (ICDs) (review) (TA95)	Procedure	No	N/A	Responsibility of NHS England
Cardiovascular disease - statins (TA94)	Drug	Yes	Yes	
Tooth decay - HealOzone (TA92)	Procedure	No	N/A	Responsibility of NHS England
Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) (TA91)	Drug	No	N/A	Responsibility of NHS England
Bradycardia - dual chamber pacemakers (TA88)	Device	Yes	Yes	Some patients may be funded by NHS England
Gastrointestinal stromal tumours - imatinib (TA86)	Drug	No	N/A	Responsibility of NHS England
Renal transplantation - immuno-suppressive regimens (adults) (TA85)	Drug	No	N/A	Responsibility of NHS England
Hernia - laparoscopic surgery (review) (TA83)	Procedure	Yes	Yes	
Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)	Drug	Yes	Yes	
Atopic dermatitis (eczema) - topical steroids (TA81)	Drug	Yes	Yes	
Menstrual bleeding - fluid-filled thermal balloon and microwave endometrial ablation (TA78)	Procedure	Yes	Yes	
Insomnia - newer hypnotic drugs (TA77)	Drug	Yes	Yes	
Hepatitis C - pegylated interferons, ribavirin and alfa interferon (TA75)	Drug	No	N/A	Responsibility of NHS England
Trauma - fluid replacement therapy (TA74)	Other	Yes	Yes	
Angina and myocardial infarction - myocardial perfusion scintigraphy (TA73)	Procedure	Yes	Yes	
Ischaemic heart disease - coronary artery stents (TA71)	Procedure	No	N/A	Responsibility of NHS England
Leukaemia (chronic myeloid) - imatinib (TA70) (partially updated by TA241 and TA251)	Drug	No	N/A	Responsibility of NHS England
Cervical cancer - cervical screening (review) (TA69)	Procedure	No	N/A	Responsibility of NHS England
Macular degeneration (age-related) - photodynamic therapy (TA68)	Procedure	Yes	Yes	
Non-Hodgkin's lymphoma - rituximab (TA65)	Drug	No	N/A	Responsibility of NHS England
Growth hormone deficiency (adults) - human growth hormone (TA64)	Drug	Yes	Yes	

Colorectal cancer - capecitabine and tegafur uracil (TA61)	Drug	No	N/A	Responsibility of NHS England
Diabetes (types 1 and 2) - patient education models (TA60)	Other	Yes	Yes	
Electroconvulsive therapy (ECT) (TA59)	Procedure	Yes	Yes	
Ovarian cancer - paclitaxel (review) (TA55)	Drug	No	N/A	Responsibility of NHS England
Diabetes (types 1 and 2) - long acting insulin analogues (TA53)	Drug	Yes	Yes	
Myocardial infarction - thrombolysis (TA52)	Drug	Yes	Yes	
Central venous catheters - ultrasound locating devices (TA49)	Device	Yes	Yes	
Renal failure - home versus hospital haemodialysis (TA48)	Procedure	No	N/A	Responsibility of NHS England
Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) (TA47) (partially updated by CG94)	Drug	Yes	Yes	Funded in line with CG94.
Hip disease - metal on metal hip resurfacing (TA44)	Device	Yes	Yes	
Asthma (older children) - inhaler devices (TA38)	Device	Yes	Yes	
Arthritis (juvenile idiopathic) - etanercept (TA35)	Drug	Yes	Yes	
Breast cancer - trastuzumab (TA34)	Drug	No	N/A	Responsibility of NHS England
Multiple sclerosis - beta interferon and glatiramer acetate (TA32)	Drug	No	N/A	Responsibility of NHS England
Leukaemia (lymphocytic) - fludarabine (TA29)	Drug	No	N/A	Responsibility of NHS England
Pancreatic cancer - gemcitabine (TA25)	Drug	No	N/A	Responsibility of NHS England
Brain cancer - temozolomide (TA23)	Drug	No	N/A	Responsibility of NHS England
Motor neurone disease - riluzole (TA20)	Drug	Yes	Yes	
Asthma (children under 5) - inhaler devices (TA10)	Device	Yes	Yes	
Hip disease - replacement prostheses (TA2)	Procedure	Yes	Yes	
Wisdom teeth - removal (TA1)	Procedure	No	N/A	Responsibility of NHS England